世界の多発性硬化症治療薬市場(2014-2018)...市場調査レポートについてご紹介

【英文タイトル】Global Multiple Sclerosis Drugs Market 2014-2018

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Betaferon/Betaseron/Extavia
04.1.2 Avonex/Rebif
04.1.3 Fampyra
04.1.4 Tecfidera
04.1.5 Tysabri
04.1.6 Gilenya
04.1.7 Copaxone
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Rate of Incidence and Prevalence
08. Market Segmentation by Molecule Type
08.1 Global Biologics Market
08.1.1 Market Size and Forecast
08.2 Global Small Molecules Market
08.2.1 Market Size and Forecast
09. Market Segmentation by Route of Administration
09.1 Global Oral Drugs Market
09.1.1 Market Size and Forecast
09.2 Global Parenteral Drugs Market
09.2.1 Market Size and Forecast
10. Geographical Segmentation
10.1 Multiple Sclerosis Market in the US
10.1.1 Market Size and Forecast
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.2.1 Bayer
18.2.2 Biogen Idec
18.2.3 Merck Serono
18.2.4 Novartis
18.2.5 Teva Pharmaceuticals
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Bayer
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Sales Segmentation by Business
19.1.6 Sales by Geographical Segmentation
19.1.7 Key Information
19.1.8 SWOT Analysis
19.2 Biogen Idec
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue 2013
19.2.4 Geographical Segmentation by Revenue 2013
19.2.5 Business Strategy
19.2.6 Key Developments
19.2.7 SWOT Analysis
19.3 Merck Serono
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Geographical Segmentation by Revenue 2013
19.3.4 Business Strategy
19.3.5 Recent Developments
19.3.6 SWOT Analysis
19.4 Novartis
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Sales by Geography
19.4.6 Business Strategy
19.4.7 Key Developments
19.4.8 SWOT Analysis
19.5 Teva Pharmaceuticals
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation
19.5.4 Business Segmentation by Revenue 2013
19.5.5 Business Segmentation by Revenue 2012 and 2013
19.5.6 Sales by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Multiple Sclerosis Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type
Exhibit 4: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013
Exhibit 5: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2018
Exhibit 6: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013-2018 (US$ billion)
Exhibit 7: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013-2018 (in percent)
Exhibit 8: Global Biologics Market 2013-2018 (US$ billion)
Exhibit 9: Global Small Molecules Market 2013-2018 (US$ billion)
Exhibit 10: Global Multiple Sclerosis Drugs Market by Route of Administration
Exhibit 11: Global Multiple Sclerosis Drugs Market by Route of Administration 2013
Exhibit 12: Global Multiple Sclerosis Drugs Market by Route of Administration 2018
Exhibit 13: Global Multiple Sclerosis Drugs Market Segmentation by Route of Administration 2013-2018 (US$ billion)
Exhibit 14: Global Multiple Sclerosis Drugs Market Segmentation by Route of Administration 2013-2018 (in percent)
Exhibit 15: Global Oral Drugs Market 2013-2018 (US$ billion)
Exhibit 16: Global Parenteral Drugs Market 2013-2018 (US$ billion)
Exhibit 17: Global Multiple Sclerosis Drugs Market by Geography 2013
Exhibit 18: Multiple Sclerosis Market in the US 2013-2018 (US$ billion)
Exhibit 19: Global Multiple Sclerosis Drugs Market by Vendor Segmentation 2013
Exhibit 20: Global Sales Comparison of Betaseron/Betaferon 2010-2013 (US$ million)
Exhibit 21: Sales of Avonex 2011-2013 (US$ million)
Exhibit 22: Sales of Tysabri 2011-2013 (US$ million)
Exhibit 23: Sales of Fampyra 2011-2013 (US$ million)
Exhibit 24: Sales Comparison of Avonex, Tysabri and Fampyra 2011-2013 (US$ million)
Exhibit 25: Sales of Rebif 2010-2013 (US$ million)
Exhibit 26: Sales of Rebif in North America 2010-2013 (US$ million)
Exhibit 27: Sales of Rebif in Europe 2010-2013 (US$ million)
Exhibit 28: Sales of Rebif in Emerging Markets and RoW 2010-2013 (US$ million)
Exhibit 29: Geography-wise Sales of Rebif 2010-2013 (US$ million)
Exhibit 30: Sales of Gilenya 2010-2013 (US$ million)
Exhibit 31: Sales of Extavia 2010-2013 (US$ million)
Exhibit 32: Sales of Gilenya and Extavia 2010-2013 (US$ million)
Exhibit 33: Quarter-wise Sales of Copaxone 2011-2013 (US$ million)
Exhibit 34: Quarter-wise Sales of Copaxone in the US 2011-2013 (US$ million)
Exhibit 35: Quarter-wise Sales of Copaxone Outside the US 2011-2013 (US$ million)
Exhibit 36: Business Segmentation of Bayer AG 2013
Exhibit 37: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
Exhibit 38: Sales Segmentation of Bayer AG by Geography 2013
Exhibit 39: Biogen Idec: Business Segmentation by Revenue 2013
Exhibit 40: Biogen Idec: Geographical Segmentation by Revenue 2013
Exhibit 41: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 42: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 43: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 44: Novartis AG: Sales by Geography 2013
Exhibit 45: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 46: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2013
Exhibit 47: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 48: Teva Pharmaceutical Industries Ltd.: Sales by Geography 2013


【レポート販売概要】

■ タイトル:世界の多発性硬化症治療薬市場(2014-2018)
■ 英文:Global Multiple Sclerosis Drugs Market 2014-2018
■ 発行日:2014年8月20日
■ 調査会社:Technavio
■ 商品コード:IRTNTR3981
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。